Quick Answer
Candel Therapeutics, Inc. reported Operating Income Loss of -$48.27 million for the year ending 2025.
- Candel Therapeutics, Inc. showed a decrease of -44.6% in Operating Income Loss from 2024 to 2025.
- This data is from Candel Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2020 to 2025), Candel Therapeutics, Inc.'s Operating Income Loss has declined by 249.5%.
- Historical annual values: Fiscal year 2025: -$48.27 million | Fiscal year 2024: -$33.37 million | Fiscal year 2023: -$38.39 million | Fiscal year 2022: -$34.72 million | Fiscal year 2021: -$25.73 million | Fiscal year 2020: -$13.81 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: